B-vitamins may delay Alzheimer’s onset


UK researchers have found that high doses of B-vitamins – including folic acid, vitamin B12 and vitamin B6 – can slow down brain tissue atrophy, a wasting process associated with Alzheimer’s disease.

David Smith of the University of Oxford, and colleagues, used randomised controlled trials to test the long-term effects of B-vitamins on the brain health of elderly people with mild cognitive impairment, who were classed as having an increased risk of dementia. They found the brains of those treated with B-vitamins shrank less over a two year period than those given a placebo, and experienced less atrophy in regions of grey matter especially vulnerable to Alzheimer’s.

They also showed that the supplements effectively reduced blood concentrations of homocysteine, high levels of which have been linked to Alzheimer’s and cognitive impairment.

The work suggests addressing non-genetic aspects of Alzheimer’s may identify better treatment options. Alzheimer’s is the most common cause of dementia, with over 25 million sufferers worldwide. Several potential treatments have failed in recent clinical trials.


Related Content

Renewed focus on dementia checked by drug challenges

3 July 2014 News and Analysis

news image

'Ticking time bomb' of global neurodegenerative disease burden will be difficult to defuse

Zinc ruled out as biomarker for Alzheimer’s disease

31 March 2014 Research

news image

Study says decreasing serum zinc levels are a sign of ageing

Most Read

UC Davis chemist sentenced to four years over explosion

19 November 2014 News and Analysis

news image

Postdoc sentenced over attempt to make explosive device and reckless disposal of hazardous waste

Spanish fly

10 October 2013 Podcast | Compounds

news image

Helen Scales looks at cantharidin, the active ingredient in this famous aphrodisiac

Most Commented

Beetle behind breath test for bank notes

17 November 2014 Research

news image

Photonic crystal inks inspired by longhorn beetle could help to fight counterfeiting

Bayer wins race to buy Merck & Co consumer care

9 May 2014 Business

news image

$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company